Ovid Therapeutics (OVID) Common Equity (2016 - 2026)

Ovid Therapeutics has reported Common Equity for 11 years, with the latest figure at $198.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 234.48% year-over-year to $198.3 million; the trailing twelve-month figure through Mar 2026 stood at $198.3 million (up 234.48% YoY), and the FY2025 full-year result was $130.7 million, up 91.51% from the prior year.
• Common Equity for Q1 2026 stood at $198.3 million, up from $130.7 million in the prior quarter.
• The five-year high for Common Equity was $198.3 million in Q1 2026, with the low at $44.7 million in Q3 2025.
• Historically, Common Equity has averaged $106.6 million across 5 years, with a median of $101.3 million in 2023.
• Annual changes were most pronounced in 2025 — Common Equity plunged 41.41% — and 2026, when it surged 234.48%.
• Ovid Therapeutics' Common Equity stood at $132.3 million in 2022, then tumbled by 33.62% to $87.8 million in 2023, then retreated by 22.29% to $68.2 million in 2024, then jumped by 91.51% to $130.7 million in 2025, then jumped by 51.74% to $198.3 million in 2026.
• The last three Common Equity figures came in at $198.3 million (Q1 2026), $130.7 million (Q4 2025), and $44.7 million (Q3 2025), per Business Quant data.